State Street: Myriad Genetics MYGN Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 20.7 M | Venta |
4,798,628
-186,432
| -4% | -USD 786 k | ﹤0.01% | 2327 |
|
|
2026
Q2 | USD 28.5 M | Compra |
4,985,060
+561,033
| +13% | +USD 2.55 M | ﹤0.01% | 2204 |
|
|
2026
Q1 | USD 19.9 M | Venta |
4,424,027
-1,542,540
| -26% | -USD 8.04 M | ﹤0.01% | 2241 |
|
|
2025
Q4 | USD 36.7 M | Compra |
5,966,567
+990,075
| +20% | +USD 7.18 M | ﹤0.01% | 1913 |
|
|
2025
Q3 | USD 36 M | Compra |
4,976,492
+166,543
| +3% | +USD 989 k | ﹤0.01% | 1917 |
|
|
2025
Q2 | USD 25.5 M | Venta |
4,809,949
-458,841
| -9% | -USD 2.71 M | ﹤0.01% | 2053 |
|
|
2025
Q1 | USD 46.7 M | Venta |
5,268,790
-256,915
| -5% | -USD 3.09 M | ﹤0.01% | 1681 |
|
|
2024
Q4 | USD 75.8 M | Compra |
5,525,705
+822,263
| +17% | +USD 15.2 M | ﹤0.01% | 1512 |
|
|
2024
Q3 | USD 129 M | Compra |
4,703,442
+359,685
| +8% | +USD 9.7 M | 0.01% | 1181 |
|
|
2024
Q2 | USD 106 M | Venta |
4,343,757
-1,059,928
| -20% | -USD 23.3 M | ﹤0.01% | 1219 |
|
|
2024
Q1 | USD 115 M | Compra |
5,403,685
+703,054
| +15% | +USD 15.1 M | 0.01% | 1215 |
|
|
2023
Q4 | USD 90 M | Compra |
4,700,631
+17,751
| +0.4% | +USD 307 k | ﹤0.01% | 1355 |
|
|
2023
Q3 | USD 75.1 M | Venta |
4,682,880
-40,108
| -0.8% | -USD 763 k | ﹤0.01% | 1367 |
|
|
2023
Q2 | USD 109 M | Compra |
4,722,988
+120,069
| +3% | +USD 2.62 M | 0.01% | 1154 |
|
|
2023
Q1 | USD 107 M | Venta |
4,602,919
-417,504
| -8% | -USD 8.48 M | 0.01% | 1141 |
|
|
2022
Q4 | USD 72.8 M | Compra |
5,020,423
+363,160
| +8% | +USD 6.77 M | ﹤0.01% | 1386 |
|
|
2022
Q3 | USD 88.9 M | Venta |
4,657,263
-146,894
| -3% | -USD 3.37 M | 0.01% | 1184 |
|
|
2022
Q2 | USD 87.3 M | Compra |
4,804,157
+607,932
| +14% | +USD 12.6 M | 0.01% | 1260 |
|
|
2022
Q1 | USD 106 M | Venta |
4,196,225
-214,178
| -5% | -USD 5.48 M | 0.01% | 1256 |
|
|
2021
Q4 | USD 122 M | Compra |
4,410,403
+115,570
| +3% | +USD 3.35 M | 0.01% | 1144 |
|
|
2021
Q3 | USD 139 M | Compra |
4,294,833
+205,528
| +5% | +USD 6.83 M | 0.01% | 1037 |
|
|
2021
Q2 | USD 125 M | Compra |
4,089,305
+54,648
| +1% | +USD 1.58 M | 0.01% | 1134 |
|
|
2021
Q1 | USD 123 M | Compra |
4,034,657
+319,127
| +9% | +USD 9.06 M | 0.01% | 1080 |
|
|
2020
Q4 | USD 73.5 M | Venta |
3,715,530
-622,352
| -14% | -USD 10 M | ﹤0.01% | 1389 |
|
|
2020
Q3 | USD 56.6 M | Venta |
4,337,882
-1,042,716
| -19% | -USD 13.2 M | ﹤0.01% | 1366 |
|
|
2020
Q2 | USD 61 M | Compra |
5,380,598
+1,284,595
| +31% | +USD 18.2 M | ﹤0.01% | 1308 |
|
|
2020
Q1 | USD 58.6 M | Compra |
4,096,003
+209,727
| +5% | +USD 4.43 M | 0.01% | 1157 |
|
|
2019
Q4 | USD 106 M | Compra |
3,886,276
+313,410
| +9% | +USD 8.62 M | 0.01% | 1010 |
|
|
2019
Q3 | USD 102 M | Venta |
3,572,866
-549,423
| -13% | -USD 16 M | 0.01% | 990 |
|
|
2019
Q2 | USD 115 M | Compra |
4,122,289
+57,067
| +1% | +USD 1.61 M | 0.01% | 944 |
|
|
2019
Q1 | USD 135 M | Compra |
4,065,222
+358,958
| +10% | +USD 10.9 M | 0.01% | 842 |
|
|
2018
Q4 | USD 108 M | Compra |
3,706,264
+257,852
| +7% | +USD 9.28 M | 0.01% | 863 |
|
|
2018
Q3 | USD 159 M | Compra |
3,448,412
+319,740
| +10% | +USD 14.2 M | 0.01% | 807 |
|
|
2018
Q2 | USD 117 M | Venta |
3,128,672
-507,997
| -14% | -USD 17.2 M | 0.01% | 934 |
|
|
2018
Q1 | USD 107 M | Compra |
3,636,669
+154,061
| +4% | +USD 5.21 M | 0.01% | 965 |
|
|
2017
Q4 | USD 120 M | Compra |
3,482,608
+375,199
| +12% | +USD 12.7 M | 0.01% | 928 |
|
|
2017
Q3 | USD 112 M | Venta |
3,107,409
-653
| -0% | -USD 18.6 k | 0.01% | 923 |
|
|
2017
Q2 | USD 80.3 M | Venta |
3,108,062
-68,364
| -2% | -USD 1.45 M | 0.01% | 1075 |
|
|
2017
Q1 | USD 61 M | Venta |
3,176,426
-412,653
| -11% | -USD 7.31 M | 0.01% | 1209 |
|
|
2016
Q4 | USD 59.8 M | Compra |
3,589,079
+488,484
| +16% | +USD 8.84 M | 0.01% | 1165 |
|
|
2016
Q3 | USD 63.8 M | Compra |
3,100,595
+939,447
| +43% | +USD 23.8 M | 0.01% | 1093 |
|
|
2016
Q2 | USD 66.1 M | Venta |
2,161,148
-38,964
| -2% | -USD 1.35 M | 0.01% | 1044 |
|
|
2016
Q1 | USD 82.3 M | Compra |
2,200,112
+188,101
| +9% | +USD 7.09 M | 0.01% | 921 |
|
|
2015
Q4 | USD 86.8 M | Compra |
2,012,011
+97,638
| +5% | +USD 4.12 M | 0.01% | 884 |
|
|
2015
Q3 | USD 71.7 M | Venta |
1,914,373
-201,242
| -10% | -USD 7.14 M | 0.01% | 974 |
|
|
2015
Q2 | USD 71.9 M | Compra |
2,115,615
+494,971
| +31% | +USD 16.8 M | 0.01% | 1048 |
|
|
2015
Q1 | USD 57.4 M | Compra |
1,620,644
+92,820
| +6% | +USD 3.32 M | 0.01% | 1155 |
|
|
2014
Q4 | USD 52 M | Compra |
1,527,824
+19,160
| +1% | +USD 680 k | 0.01% | 1209 |
|
|
2014
Q3 | USD 58.2 M | Venta |
1,508,664
-142,313
| -9% | -USD 5.31 M | 0.01% | 1094 |
|
|
2014
Q2 | USD 64.3 M | Venta |
1,650,977
-120,147
| -7% | -USD 4.47 M | 0.01% | 1094 |
|
|
2014
Q1 | USD 60.6 M | Venta |
1,771,124
-210,607
| -11% | -USD 6.52 M | 0.01% | 1102 |
|
|
2013
Q4 | USD 41.6 M | Venta |
1,981,731
-175,664
| -8% | -USD 4.44 M | ﹤0.01% | 1308 |
|
|
2013
Q3 | USD 50.7 M | Compra |
2,157,395
+368,403
| +21% | +USD 10.5 M | 0.01% | 1157 |
|
|
2013
Q2 | USD 48.1 M | Compra |
+1,788,992
| Nuevas | +USD 51.9 M | 0.01% | 1138 |
|
Otros fondos que tienen MYGN en su portafolio
Posición de State Street en MYGN: resumen de T3 2026
State Street redujo su participación en Myriad Genetics (MYGN) en 3.7% durante T3 2026, al vender acciones por un valor estimado de USD 786 k y quedarse con 4,798,628 acciones valuadas en USD 20.7 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #2327.
State Street reportó por primera vez una posición en MYGN en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 159 M en T3 2018. Al cierre de T3 2026, 176 fondos que sigue Wall St. Rank mantienen una posición en MYGN.
- Al cierre de T3 2026, State Street tenía 4,798,628 acciones de Myriad Genetics con un valor de USD 20.7 M.
- State Street vendió 186,432 acciones de Myriad Genetics en T3 2026, por un valor estimado de USD 786 k.
- Myriad Genetics representó el ﹤0.01% del portafolio de State Street en T3 2026 y fue su posición número 2327.
- State Street reportó por primera vez una posición en Myriad Genetics en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de State Street en Myriad Genetics alcanzó su máximo de USD 159 M en T3 2018.
- Al cierre de T3 2026, 176 fondos que sigue Wall St. Rank tenían Myriad Genetics en su portafolio.
Según el informe 13F de State Street correspondiente a T3 2026, presentado el 12 nov 2026.